Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936998 · ClinicalTrials.gov registry record · Phase 1
VE416 for Treatment of Food Allergy
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03936998: Recruiting Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03936998 is a Phase 1 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936998, a Phase 1 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-blind trial with four arms evaluating VE416 as pretreatment or concurrent treatment in comparison to low-dose peanut oral immunotherapy (PNOIT) alone.
Interventions
- COMBINATION_PRODUCT Vancomycin plus VE416 before PNOIT
- COMBINATION_PRODUCT Vancomycin plus VE416 with PNOIT
- COMBINATION_PRODUCT Placebo plus VE416 with PNOIT
- COMBINATION_PRODUCT Placebo plus placebo with PNOIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03936998
The ClinicalTrials.gov registry entry for NCT03936998 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vancomycin plus VE416 before PNOIT is the first listed.
NCT03936998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03936998 about?
NCT03936998 is a clinical study titled "VE416 for Treatment of Food Allergy". This is a single-center, randomized, double-blind trial with four arms evaluating VE416 as pretreatment or concurrent treatment in comparison to low-dose peanut oral immunotherapy (PNOIT) alone.
What is the current status of trial NCT03936998?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2019-06-28. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT03936998?
The interventions under investigation include: Vancomycin plus VE416 before PNOIT (COMBINATION_PRODUCT), Vancomycin plus VE416 with PNOIT (COMBINATION_PRODUCT), Placebo plus VE416 with PNOIT (COMBINATION_PRODUCT), Placebo plus placebo with PNOIT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03936998?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.